GLP-3 15mg

Introduction to GLP-3 Peptide

GLP-3 (LY3437943) is a synthetic peptide engineered to serve as a triple-agonist, simultaneously targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. This 39-amino-acid peptide is designed for enhanced stability and pharmacokinetics through conjugation with a fatty diacid moiety, resulting in a six-day half-life. This extended half-life and robust stability make GLP-3 an exceptional tool for preclinical studies, particularly those investigating complex physiological processes such as metabolic regulation, weight management, and tissue repair. Unlike single- or dual-agonist peptides, the ability of GLP-3 to engage three receptors synergistically offers researchers a unique opportunity to explore multifaceted pathways in controlled laboratory settings. This comprehensive examination covers chemical properties, mechanisms of action, and research applications while strictly adhering to laboratory research guidelines.

Chemical and Structural Properties of GLP-3

The design of GLP-3 is rooted in a GIP backbone, modified to amplify the biological activities of GLP-1, GIP, and glucagon, creating a versatile platform for preclinical research. Its lyophilized form ensures long-term stability when stored at -20°C or below, preventing degradation and maintaining bioactivity for extended experimental protocols. The peptide’s conjugation with a fatty diacid enhances its pharmacokinetic profile, allowing for once-weekly dosing in animal models, which is particularly advantageous for longitudinal studies requiring consistent exposure.

• Molecular Architecture: Derived from a GIP backbone with triple-receptor agonism.

• Format: Lyophilized for stability at -20°C or lower.

• Pharmacokinetics: Six-day half-life supports once-weekly dosing.

• Bioavailability: Fatty diacid conjugation enhances research viability.

Mechanisms of Action

The efficacy of GLP-3 in preclinical research stems from its ability to engage GLP-1, GIP, and glucagon receptors, producing a synergistic effect on metabolic and regenerative pathways. Its multi-receptor agonism allows it to modulate glucose homeostasis, lipid metabolism, energy expenditure, and inflammation.

• GLP-1 Receptor Agonism: GLP-3 enhances glucose-dependent insulin secretion from pancreatic beta cells, reducing blood glucose levels without risking hypoglycemia in research models. Coskun et al., 2022

• GIP Receptor Agonism: With 8.9 times greater potency than native GIP, GLP-3 amplifies insulin secretion and promotes lipid metabolism. Preclinical rodent studies have shown significant weight loss driven by GIP-mediated appetite suppression.

• Glucagon Receptor Agonism: GLP-3 increases energy expenditure via hepatic glucose production and thermogenesis. It also reduces hepatic lipid accumulation. Sanyal et al., 2024

• Anti-Inflammatory and Tissue Repair Effects: By modulating cytokine expression, GLP-3 supports tissue regeneration in organs like the liver and kidney. Ma et al., 2024

GLP-3 Peptide Research

1. GLP-3 and Metabolic Health Models

Achieved a 24.2% weight reduction in obese mice over 48 weeks, making GLP-3 ideal for studying neuroendocrine pathways. This research helps illuminate how triple-receptor agonism affects long-term metabolic balance. Jastreboff et al., 2023

2. Type 2 Diabetes Markers

GLP-3 reduces HbA1c and improves insulin sensitivity in diabetic rodents. These findings suggest it is an effective tool for examining how multi-receptor incretin agonists affect glucose handling. Rosenstock et al., 2023

3. Liver Fat and MASLD Models

GLP-3 decreases liver fat and improves histological markers in mouse models, making it a primary focus for labs exploring steatosis, scarring, and metabolic syndrome risk. Sanyal et al., 2024

4. Cardiovascular and Renal Tissue Repair

By reducing inflammation and fibrosis, GLP-3 shows potential in diabetic kidney disease models and cardiovascular tissue studies. Researchers are using it to study anti-inflammatory and angiogenic properties in various organ systems. Ma et al., 2024

Research Considerations and Limitations

Conducting preclinical research with GLP-3 requires careful attention to regulatory, scientific, and ethical considerations. Its status as a research-only peptide necessitates strict adherence to laboratory protocols.

• Regulatory Compliance: Restricted to laboratory research; not approved for human consumption.

• Dosing and Administration: Subcutaneous doses require model-specific calibration for reproducibility.

• Clinical Status: Research is ongoing with phase 3 trials continuing as of late 2023. Ray, 2023

GLP-3 Peptide Specifications Table

GLP-3 Peptide FAQs

What is GLP-3 peptide used for in research?

In research, GLP-3 peptide is used to study the synergistic effects of activating GLP-1, GIP, and glucagon receptors. This allows scientists to investigate changes in body weight, glucose control, and liver fat in preclinical models. Coskun et al., 2022

How is GLP-3 peptide 15 mg per vial typically stored?

Labs store GLP-3 peptide 15 mg vials as lyophilized powder in a cool, dry, and dark environment, preferably at or below -20°C. Once reconstituted, it should be kept refrigerated or frozen according to laboratory SOPs.

Is GLP-3 peptide different from dual agonists?

Yes, GLP-3 is a triple agonist, whereas dual agonists (like GLP-2) only target two receptors. The addition of the glucagon receptor agonism in GLP-3 is studied for its potential to further increase energy expenditure.

Where can I buy GLP-3 for my laboratory?

Qualified researchers can buy GLP-3 online from Protide Health. Every compound is strictly labeled for laboratory use and is backed by thorough third-party testing.

Conclusion: Summary of GLP-3 Peptide for Research

GLP-3, a triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, offers transformative potential in preclinical research. Its synergistic effects on glucose homeostasis, lipid metabolism, energy expenditure, and inflammation enable comprehensive studies in obesity, type 2 diabetes, and tissue repair. With a six-day half-life and lyophilized stability, GLP-3 is ideal for long-term experimental protocols. By adhering to ethical standards, researchers can leverage GLP-3 to deepen understanding of complex physiological processes.

Citations

• Coskun T et al., 2022. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism.

• Jastreboff AM et al., 2023. Triple-hormone-receptor agonist GLP-3 for obesity. New England Journal of Medicine.

• Sanyal AJ et al., 2024. GLP-3 for metabolic dysfunction-associated steatotic liver disease. Nature Medicine.

• Ma J et al., 2024. Effects of GLP-3 on diabetic kidney disease in db/db mice. Endocrine.

• Rosenstock J et al., 2023. GLP-3 for type 2 diabetes. The Lancet.

• Ray A. (2023). GLP-3 for obesity management. Expert Opinion on Investigational Drugs.

Legal Disclaimer

The information provided in this description is for research purposes only. The GLP-3 peptide is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for human consumption or therapeutic use. It is intended solely for investigational use in controlled laboratory settings by qualified researchers. Researchers must comply with all applicable local, state, and federal regulations. Products sold by Protide Health are for laboratory research purposes only and are not intended for human consumption, medical use, or veterinary use.